Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION Phase II Single-Arm Tepotinib Trial in Advanced NSCLC with MET Alterations
jRCT2080223315Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Started Oct 2016; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223315.